Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Survey of Buprenorphine Use Among "Out of Care" Population in France (P04933)(COMPLETED)

This study has been completed.
Sponsor:
Information provided by:
Reckitt Benckiser Pharmaceuticals Inc.
ClinicalTrials.gov Identifier:
NCT00756353
First received: September 19, 2008
Last updated: April 14, 2011
Last verified: September 2008
  Purpose

This study was a survey of drug users who obtain buprenorphine from the black market and have used buprenorphine during the last month. Subjects were surveyed at various locations (streets, railway stations, etc.) with a few simple questions in order to describe the use of buprenorphine in this "out of care" population.


Condition
Drug Addiction

Study Type: Observational
Study Design: Time Perspective: Cross-Sectional
Official Title: Out of Care Patient Survey

Resource links provided by NLM:


Further study details as provided by Reckitt Benckiser Pharmaceuticals Inc.:

Primary Outcome Measures:
  • The objective of this survey is to describe quantitatively and qualitatively, the use of buprenorphine in the population who obtain buprenorphine only on black market or both on black market and in pharmacy. [ Time Frame: Not Applicable, cross-sectional description. ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • This survey will provide data on patients in regards to their own experience in drug addiction. [ Time Frame: Not Applicable, cross-sectional description. ] [ Designated as safety issue: No ]

Enrollment: 600
Study Start Date: June 2006
Study Completion Date: December 2006
Primary Completion Date: December 2006 (Final data collection date for primary outcome measure)
Groups/Cohorts
Wave 1
Wave 2

Detailed Description:

Participants were found from various places and using a "snow ball" technique.

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

The population in this survey includes drug users who are in the "out of care" population, found in various places (streets, railway stations) and via the "snow ball" technique.

Criteria

Inclusion Criteria:

  • Drug users who have obtained buprenorphine only on the black market or both on black market and in pharmacy.

Exclusion Criteria:

  • Patients who have obtained buprenorphine only from the pharmacy.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

No Contacts or Locations Provided
  More Information

No publications provided

Responsible Party: Head, Clinical Trials Registry & Results Disclosure Group, Schering-Plough
ClinicalTrials.gov Identifier: NCT00756353     History of Changes
Other Study ID Numbers: P04933
Study First Received: September 19, 2008
Last Updated: April 14, 2011
Health Authority: France: Not Applicable

Keywords provided by Reckitt Benckiser Pharmaceuticals Inc.:
Heroin
Buprenorphine use

Additional relevant MeSH terms:
Buprenorphine
Analgesics
Analgesics, Opioid
Central Nervous System Agents
Central Nervous System Depressants
Narcotic Antagonists
Narcotics
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sensory System Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on November 25, 2014